- Home
- HSII vs GYRE Comparison
HSII vs GYRE Comparison
Compare HSII & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSII
- GYRE
- Stock Information
- Founded
- HSII 1953
- GYRE 2002
- Country
- HSII United States
- GYRE United States
- Employees
- HSII N/A
- GYRE N/A
- Industry
- HSII Diversified Commercial Services
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- HSII Consumer Discretionary
- GYRE Health Care
- Exchange
- HSII Nasdaq
- GYRE Nasdaq
- Market Cap
- HSII 904.3M
- GYRE 897.1M
- IPO Year
- HSII 1999
- GYRE N/A
- Fundamental
- Price
- HSII $43.22
- GYRE $8.12
- Analyst Decision
- HSII Buy
- GYRE
- Analyst Count
- HSII 2
- GYRE 0
- Target Price
- HSII $48.00
- GYRE N/A
- AVG Volume (30 Days)
- HSII 128.1K
- GYRE 337.8K
- Earning Date
- HSII 05-05-2025
- GYRE 05-09-2025
- Dividend Yield
- HSII 1.37%
- GYRE N/A
- EPS Growth
- HSII N/A
- GYRE N/A
- EPS
- HSII 0.37
- GYRE 0.02
- Revenue
- HSII $1,116,954,000.00
- GYRE $100,643,000.00
- Revenue This Year
- HSII $6.05
- GYRE $22.01
- Revenue Next Year
- HSII $1.89
- GYRE $88.14
- P/E Ratio
- HSII $118.87
- GYRE $112.98
- Revenue Growth
- HSII 6.10
- GYRE N/A
- 52 Week Low
- HSII $30.20
- GYRE $6.11
- 52 Week High
- HSII $49.02
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- HSII 58.38
- GYRE 43.10
- Support Level
- HSII $40.10
- GYRE $9.26
- Resistance Level
- HSII $44.70
- GYRE $11.61
- Average True Range (ATR)
- HSII 1.17
- GYRE 1.04
- MACD
- HSII 0.04
- GYRE -0.26
- Stochastic Oscillator
- HSII 58.63
- GYRE 14.06
About HSII Heidrick & Struggles International Inc.
Heidrick & Struggles International Inc is a leadership advisory firm providing executive search and consulting services to businesses and business leaders world wide. The company's operating segments includes the executive search business which operates in the Americas; Europe; Asia Pacific and On-Demand Talent and Heidrick Consulting. It generates maximum revenue from the Americas.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.